1 / 30

Tocilizumab (RoACTEMRA): a New Therapeutic Approach in Rheumatoid Arthritis

Tocilizumab (RoACTEMRA): a New Therapeutic Approach in Rheumatoid Arthritis. Ronald F van Vollenhoven Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden. Clinical case.

akeem-graves
Download Presentation

Tocilizumab (RoACTEMRA): a New Therapeutic Approach in Rheumatoid Arthritis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tocilizumab (RoACTEMRA): a New Therapeutic Approach in Rheumatoid Arthritis Ronald F van Vollenhoven Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden

  2. Clinical case

  3. IL-6 is produced by multiple cell types and is associated with numerous biological activities Monocytes/ macrophages Mesenchymal cells, fibroblasts/ synoviocytes Endothelial cells T-cell activation IL-6 Hepatocytes Neutrophils Acute-phase proteins, e.g. hepcidin, CRP Maturation of megakaryocytes B cells Osteoclast activation Bone resorption Hyper--globulinaemia Thrombocytosis Auto-antibodies (RF) Choy E. Rheum Dis Clin N Am 2004;30:405415.Rose-John S, et al. Expert Opin Ther Targets 2007;11:613–624.

  4. Articular effects of IL-6 in RA B cell Antibody production1 Synoviocytes VEGF2 IL-6 Macrophage Endothelial cells Pannus formation3 MMPs4 T cell Neutrophil Joint destruction1 Osteoclast activation, bone resorption Mediation of chronic inflammation5 1Choy E. Rheum Dis Clin North Am 2004;30:405–415.2Nakahara H, et al. Arthritis Rheum 2003;48:15211529.3Yoshizaki K, et al. Springer Semin Immunopathol 1998;20:247259. 4Smolen J, et al. Nat Rev Drug Disc 2003;2:473–488. 5Gabay C. Arthritis Res Ther. 2006;8 (Suppl 2):S3.

  5. Systemic effects of IL-6 in RA Acute-phase response1 Acute-phase proteins (e.g. CRP) IL-6 Hepcidin production Alterations in iron homeostasis2 Thrombocytosis1 Osteoporosis1 Hypothalamus/pituitary/adrenal axis5 Alterations in lipid metabolism3,4 Mood/fatigue/pain6 1Choy E. Rheum Dis Clin North Am 2004;30:405–415. 2McGrath H & Rigby P. Rheumatology 2004;43:1323–1325. 3Al-Khalili L, et al. Mol Endocrinol 2006;20:3364–3375. 4van Hall G, et al. J Clin Endocrinol Metab 2003;88:3005–3010. 5Perlstein R, et al. Endocrinology 1993;132:946952. 6Chrousos G. N Engl J Med 1995;332:1351–1362.

  6. Tocilizumab (RoACTEMRA): anti-IL6 1- Efficacy

  7. 37 29 12 Phase III clinical trials with tocilizumab in RA: ACR50 and ACR70 responses MTX-naïve DMARD-IR Anti-TNF-IR p=0.0023 p=0.0002 Tocilizumab 8 mg/kg 44 45 p<0.0001 p<0.0001 Control 40 34 35 p<0.0001 p<0.001 9 30 28 25 Patients (%) 19 20 15 15 10 10 4 5 2 1 0 ACR50 ACR70 ACR50 ACR70 ACR50 ACR70 AMBITION1 RADIATE3 POOLED: LITHE + OPTION + TOWARD2 1Jones G, et al. Ann Rheum Dis 2009 [epub].2Data on file, F. Hoffmann-La Roche pooled analysis: LITHE, OPTION, TOWARD. 3Emery P, et al. Ann Rheum Dis 2008;67:1516–1523.

  8. Phase III clinical trials with tocilizumab in RA: good/moderate EULAR response MTX-naïve DMARD-IR Anti-TNF-IR Tocilizumab8 mg/kg 100 Odds ratio: 4.2 (95% CI 2.9–6.1) p≤0.0001 p<0.0001 Good 82 78 Moderate 80 68 65 Control 40 60 40 Good 17 EULAR response (%) Moderate 37 36 40 5 17 48 42 20 38 2 31 31 15 0 AMBITION1 RADIATE3,4 POOLED: LITHE + OPTION + TOWARD2 1Jones G, et al. Ann Rheum Dis 2009 [epub]. 2Data on file, F. Hoffmann-La Roche pooled analysis: LITHE, OPTION, TOWARD.3Emery P, et al. Ann Rheum Dis 2008;67:1516–1523. 4Data on file, F. Hoffmann-La Roche clinical study report: RADIATE.

  9. Phase III clinical trials with tocilizumab in RA: DAS28 remission (<2.6) MTX-naïve/free DMARD-IR Anti-TNF-IR Tocilizumab 8 mg/kgmonotherapy (n=286) Tocilizumab8 mg/kg + DMARD (n=1,406) Tocilizumab8 mg/kg + MTX (n=170) MTX monotherapy (n=284) Placebo + DMARD (n=1,010) Placebo + MTX (n=158) Odds ratio: 5.8 (95% CI 3.3─10.4) p<0.0001 p=0.0001 40 34 31 30 30 Patients (%) 20 12 10 3 2 0 AMBITION1 POOLED: LITHE + OPTION + TOWARD2 RADIATE3 1Jones G, et al. Ann Rheum Dis 2009 [epub]. 2Data on file, F. Hoffmann-La Roche pooled analysis: LITHE, OPTION, TOWARD.3Emery P, et al. Ann Rheum Dis 2008;67:1516–1523.

  10. Phase III clinical trials with tocilizumab in RA: low disease activity (DAS28<3.2) MTX-naïve DMARD-IR Anti-TNF-IR Tocilizumab 8 mg/kg + MTX (n=170) Tocilizumab 8 mg/kgmonotherapy (n=286) Tocilizumab 8 mg/kg + DMARD (n=1,406) MTX monotherapy (n=284) Placebo + DMARD (n=1,010) Placebo + MTX (n=158) p<0.0001 60 51 50 47 46 40 Patients (%) 30 19 20 10 7 5 0 AMBITION1† POOLED: LITHE + OPTION + TOWARD2 RADIATE2 1Data on file, F. Hoffmann-La Roche clinical study report: AMBITION. 2Data on file, F. Hoffmann-La Roche pooled analysis: LITHE, OPTION, TOWARD.3Emery P, et al. Ann Rheum Dis 2008;67:1516–1523.

  11. = infusions Tocilizumab induces rapid and durable normalisation of CRP • In patients with severe active disease (DAS28 ~6.7) at baseline, tocilizumab normalised CRP in >90% of patients within 2 weeks Placebo + DMARD (n=1,170) MTX (n=284) 3.5 Tocilizumab 8 mg/kg (n=288) 3.0 Tocilizumab 8 mg/kg + DMARD (n=1,582) 2.5 2.0 Mean CRP (mg/dl) 1.5 1.0 0.5 ULN=0.3 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (weeks) Pooled analysis of AMBITION, OPTION, TOWARD, LITHE and RADIATEULN = upper limit of normal Genovese M, et al. ACR 2008; Poster 987.

  12. Tocilizumab monotherapy vs. MTX: AMBITION trial, ACR responses at 24 weeks MTX-naïve† 100 MTX (n=190) 90 Tocilizumab 8 mg/kg (n=191) p<0.004 80 69 70 60 p=0.01 54 Patients (%) 50 45 p=0.005 40 33 27 30 20 14 10 0 ACR70 ACR20 ACR50 *Post-hoc analysis†Subset of patients never exposed to MTX Jones G et al. Ann Rheum Dis 2009 [epub].

  13. Tocilizumab vs. placebo: radiographic progression at week 52 (LITHE trial) Placebo + MTX (n=393) Tocilizumab 8 mg/kg + MTX (n=398) p<0.0001 1.2 1.1 1.0 p<0.0001 0.8 0.7 p<0.01 0.6 Mean change from baseline 0.4 0.4 0.3 0.2 0.2 0.1 (n=290) (n=348) (n=290) (n=348) (n=290) (n=348) 0 Total Sharp– Genant score Erosion score JSN score Numbers in parentheses are the total numbers of patients who reached the time point and had valid assessmentsJSN = joint space narrowing Kremer J, et al. ACR 2008; Abstract L14.Data on file, F. Hoffmann-La Roche clinical study report: LITHE.

  14. Tocilizumab efficacy • Efficacy demonstrated in various RA populations • TNF-failure, DMARD-failure, MTX-naive • As combination with MTX, as monotherapy • Robust ACR and EULAR responses • Significant proportions of patients achieve LDA or remission • Radiographic efficacy at week 52 (LITHE)

  15. Tocilizumab (RoACTEMRA): anti-IL6 2- Safety

  16. Summary of clinical trials and patients in the all-exposure population TCZ administered once every 4 weeks unless otherwise indicated PBO=placebo; DMARD-IR/TNF-IR=patients with an inadequate response to DMARD/anti-TNF therapy

  17. All-exposure population: Patient retention Cut-off date: 10 March 2008

  18. Tocilizumab exposure during the clinical trial programme (Roche and Chugai) up to 30 June 2008 * Patient-years of exposure are estimated† For Roche, this included a drug-drug interactions study in RA patients (23 patients dosed at 10 mg/kg) ‡Some patients received 4 mg/kg and 8 mg/kg and are accounted for twice in the number for ‘<8’ and ‘≥8’ but only once in the ‘total all doses’ category

  19. Adverse events • Rate of withdrawal attributed to AEs = 6.5/100 PY All-exposure population

  20. Serious infections • Most common infections were pneumonia (n=66) and cellulitis (n=31) • Nine opportunistic infections were reported (0.2/100 PY) • M. avium complex infection, TB (n=2), mycobacterial urinary tract infection, P. jiroveci pneumonia, Candida osteomyelitis, GI candidiasis, fungal oesophagitis and fungal sinusitis All-exposure population

  21. Rates of serious infections • Overall rate of serious infections = 4.37/100 PY (n=249) • Rate of deaths attributed to infections = 0.18/100 PY (n=10) All-exposure population

  22. Overview of M. tuberculosis cases: six reported In all cases, tocilizumab treatment was discontinued TCZ worldwide RA safety database

  23. Patients reporting neutropenia • Clinically significant neutropenia was detected during at least one visit in 156/3,857 (4%) of patients (grade 3, n=139;grade 4, n=17) All-exposure population

  24. Infusion-related events • Overall rate of infusion reactions: • During infusion = 2.8/100 PY • Within 24 hours of infusion = 5.7/100 PY • Clinically significant infusion reactions resulting in treatment discontinuation reported in 15 patients (0.4%) • 8 anaphylactic reactions (0.2%) • 3 infusion-related events (<0.1%) • Hypersensitivity (<0.1%) • Palpitations (<0.1%) • Syncope (<0.1%) • Allergic dermatitis (<0.1%) All-exposure population

  25. Gastrointestinal perforations • Including Roche and Chugai databases (to 30 June 2008): N=5,395; exposure, 9,948 PY • Upper GI tract perforations = 0.6/1,000 PY • Lower GI tract perforations = 1.7/1,000 PY All-exposure population

  26. Cardiovascular events • The most frequent cardiovascular events were arrhythmias and ischaemic events All-exposure population

  27. Malignancies • 81 were confirmed malignancies, 9 were benign neoplasms and 5 were unspecified neoplasms All-exposure population

  28. Percentage of patients with single elevations in transaminase levels ALT AST • 67 (1.7%) patients discontinued treatment because of elevations in transaminase levels • Elevations in transaminase levels were not associated with clinical hepatic events All-exposure population

  29. Tocilizumab safety summary • No new safety signals emerged after prolonged exposure to TCZ • Incidences and types of AEs reported after long-term exposure to TCZ were similar to those reported in controlled 6-month studies • Rates of serious infections, malignancy and other SAEs did not increase with continued treatment with TCZ • With >10,000 patient-years of TCZ exposure, six cases of Mycobacterium tuberculosis infection have been reported • The incidence of elevations in ALT/AST levels did not increase after prolonged administration of TCZ • Elevations in lipid levels were observed with TCZ treatment and decreased when statins were prescribed • Rates of MI/stroke were comparable with those reported for RA patients receiving biologics (<0.5 per 100 PY) and remained stable over time

  30. Final Conclusions • The tocilizumab clinical trials data demonstrate efficacy across RA patient populations and disease outcomes, and a well-defined and manageable safety profile • Together, these findings support a favourable risk/benefit ratio for tocilizumab in patients with rheumatoid arthritis

More Related